Trials / Unknown
UnknownNCT03609541
Evaluation of Biomarkers of COPD Exacerbation
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 80 (estimated)
- Sponsor
- Heidelberg University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Serum amlyoid A (SAA) was shown to act as biomarker for exacerbation of chronic obstructive pulmonary disease (AE-COPD). It seems that SAA triggers chronic inflammation by binding to ALX/PFR2 receptor. In contrast, lipoxin A4 seems to inhibit the inflammatory processes by binding to ALX/PFR2 receptor. A small trial has already demonstrated an imbalance between SAA and lipoxin A4 during AE-COPD. This study evaluates SAA level and SAA/lipoxin A4 ratio in patients with stable COPD and AE-COPD.
Detailed description
Patient enrolment and data aquisition is to be carried out on a prospective basis. It is planned to enrol 40 patients with stable COPD and 40 patients with AE-COPD. All patients will undergo blood sampling inlcuding SAA and Lipoxin A4.
Conditions
Timeline
- Start date
- 2018-07-01
- Primary completion
- 2023-06-01
- Completion
- 2023-06-01
- First posted
- 2018-08-01
- Last updated
- 2022-07-06
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT03609541. Inclusion in this directory is not an endorsement.